Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

EXTON, Pa., May 18 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) was honored with a Corporate Award at the National Organization for Rare Disorders (NORD) Annual Gala for its work in bringing Cinryze(TM) (C1 esterase inhibitor (human)) to market for a rare and devastating disorder -- hereditary angioedema (HAE).

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of swelling affecting the larynx, abdomen, face, extremities and urogenital tract. There are estimated to be at least 4,600 people with HAE in the United States.

"We are honored to be recognized by NORD for our work in bringing Cinryze to HAE patients in the U.S.," said Vincent Milano, ViroPharma's president and chief executive officer, "but what is even more gratifying for everyone at ViroPharma is making a difference in the lives of HAE patients who have literally been waiting for decades for this therapy."

Cinryze (C1 esterase inhibitor (human)) was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against HAE attacks in adults and adolescents. In February 2009, ViroPharma was granted priority review of a supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. If approved, Cinryze may be the first C1 esterase inhibitor available for the acute treatment for this condition. ViroPharma's Prescription Drug User Fee Act (PDUFA) date for the use of Cinryze for acute attacks in patients with HAE is June 3, 2009.

The NORD Gala is an annual event at which researchers and others are honored for significant achievements to im
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 ... an LC/MS amino acid analysis system developed jointly ... the UF-Amino Station can analyze 38 amino acids ... The UF-Amino Station achieves high-speed analysis utilizing a ... The LCMS-2020 provides accurate analytical results even under ...
(Date:7/23/2014)... 2014 StemGenex® , the leading ... US aimed at improving the lives of patients dealing ... for Parkinson’s disease. StemGenex believes that a commitment ... are paramount when providing care to patients with degenerative ... cell therapy accessible to the millions of individuals currently ...
(Date:7/23/2014)... 23, 2014 regulated information -- UCB today announced ... pipeline with positive topline results from the latest ... was designed to evaluate the efficacy and safety ... without titration) compared to placebo, as adjunctive treatment ... not fully controlled despite treatment with one or ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Mass., Oct. 10 Targanta,Therapeutics Corporation (Nasdaq: TARG ... of 5,750,000 shares of its common stock at a ... the shares are being offered by,Targanta. Targanta has granted ... an additional 862,500 shares of common stock at the ...
... Signalife has received,additional sales orders in excess of ... Lowell Harmison,s most recent cross-country sales,initiative. These purchase orders ... the company anticipates achieving break-even status,by the end of ... of 2008 first,quarter. About Signalife: Signalife, Inc. ...
... 10 DermTech International, Inc.,a biotechnology company ... of melanoma and other diseases, today appointed ... Board. Dr. Quackenbush is a,Professor of Biostatistics ... and Professor of Computational Biology and Bioinformatics,at ...
Cached Biology Technology:Targanta Therapeutics Announces Pricing of its Initial Public Offering 2Signalife Continues to Procure Purchase Orders, Revenues 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:7/24/2014)... gut that has gone undetected by scientists for decades. ... State University has found that more than half the ... named crAssphage, which infects one of the most common ... of bacteria is thought to be connected with obesity, ... in Nature Communications ., Robert A. Edwards, a ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... of Defense recently awarded the STEMPREP Project at ... support its goal of increasing the number of ... minority middle school students for the two-summer classroom ... school students with summer opportunities at research labs. ... Simmons School of Education and Human Development, boasts ...
Breaking Biology News(10 mins):Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... NY, June 27, 2011Sophisticated genetic tools and techniques for ... in bone marrow will drive the successful application of ... Examples of these cutting-edge methods are presented in a ... of Human Gene Therapy , a peer-reviewed journal ...
... A team of researchers from the National Institute ... and the University of Maryland has made nano-sized ... from paints, cleaners, pesticides and other productsthat offer ... low-power room-temperature operation and the ability to detect ...
... Most previous studies have indicated that people in cities have ... country. By using more complex methods of analysis than in ... that people,s carbon emissions are practically the same in the ... CO 2 emissions that cause climate change are dependent ...
Cached Biology News:The promise of stem cell-based gene therapy 2Nanowire-based sensors offer improved detection of volatile organic compounds 2City dwellers produce as much CO2 as countryside people do 2
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... to ThPok ( Abpromise for all tested ... conjugated to KLH derived from within residues 500 ... the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: